Search results for "DISEASE ACTIVITY SCORE"

showing 3 items of 3 documents

Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis

2020

Made available in DSpace on 2021-06-25T10:38:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-11-01 Healthway Objective. To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. Methods. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 wee…

MaleClinical assessment; Composite disease activity score; Disease activity; Outcome measures; Pediatric rheumatology; Still's disease; Systemic juvenile idiopathic arthritismedicine.medical_specialtyFeverClinical assessmentComposite disease activity scoreArthritisLymphadenopathyDiseaseSeverity of Illness IndexOutcome measuresOutcome measureJuvenile Arthritis Disease Activity ScoreRheumatologyCronbach's alphaSystemic juvenile idiopathic arthritisInternal medicineStill's diseaseContent validityMedicineJuvenileHumansPharmacology (medical)Pediatric rheumatologyDisease activityRange of Motion ArticularChildPain MeasurementSerositisThrombocytosisbusiness.industryConstruct validityReproducibility of ResultsAnemiaExanthemamedicine.diseaseArthralgiaRheumatologyArthritis JuvenileChild PreschoolSplenomegalyQuality of LifeFemaleHyperferritinemiabusinessHepatomegaly
researchProduct

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.

2014

Objective.To evaluate the safety and efficacy of therapy with etanercept and methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and mild hepatitis C virus (HCV) infection.Methods.In this prospective open study, 29 patients with active RA were randomly assigned to receive therapy with MTX alone, etanercept alone, or a combination of MTX and etanercept, and monitored up to 54 weeks. The primary endpoint was safety; secondary aims were efficacy as defined by the 44-joint Disease Activity Score (DAS44) and health assessment questionnaire (HAQ). Serum liver enzymes and HCV viral load were serially measured.Results.In the whole cohort, aspartate aminotransferase (AST) serum leve…

MaleSettore MED/16 - REUMATOLOGIATNF-α INHIBITORSHEALTH ASSESSMENT QUESTIONNAIREHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologySeverity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidDISEASE ACTIVITY SCORELiver Function TestsRheumatoidReceptorsImmunology and AllergyProspective StudiesGISEAbiologyAlanine TransaminaseHepatitis CMiddle AgedViral LoadHepatitis CTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsCombinationDrug Therapy CombinationFemaleTRANSAMINASESViral loadmedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyHepatitis C virusImmunologyDrug TherapyRheumatologyInternal medicinemedicineHumansAspartate AminotransferasesAgedHepatitisbusiness.industryArthritisTNF-alpha INHIBITORS TRANSAMINASES GISEA DISEASE ACTIVITY SCORE HEALTH ASSESSMENT QUESTIONNAIREmedicine.diseaseRheumatologyMethotrexateAlanine transaminaseImmunoglobulin GImmunologybiology.proteinTumor Necrosis FactorbusinessThe Journal of rheumatology
researchProduct

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis : 6-year efficac…

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and t…

Malelcsh:Diseases of the musculoskeletal systemArthritisCHILDRENCATEGORIESDISEASE-ACTIVITYEtanerceptEtanerceptEnthesitis-related arthritis (ERA)Juvenile Arthritis Disease Activity ScoreDOUBLE-BLINDINITIATIONNECROSIS-FACTORDEFINING CRITERIAMedicine and Health SciencesMedicineChildNon-U.S. Gov'tClinical trial; Efficacy; Enthesitis-related arthritis; Enthesitis-related arthritis (ERA); Etanercept; Extended oligoarticular juvenile idiopathic arthritis (eoJIA); Juvenile idiopathic arthritis; Psoriatic arthritis (PsA); SafetyOligoarthritisResearch Support Non-U.S. Gov'tMETHOTREXATEClinical trialTreatment OutcomeAntirheumatic AgentsChild PreschoolFemaleSafetymedicine.drugResearch Articlemedicine.medical_specialtyAdolescentEfficacyEnthesitis-related arthritisResearch SupportPsoriatic arthritisPsoriatic arthritis (PsA)Internal medicineAdalimumabJournal ArticleHumansetanercept ; juvenile idiopathic arthritis ; enthesitis-related arthritis ; extended oligoarticular juvenile idiopathic arthritis (eoJIA) ; enthesitis-related arthritis (ERA) ; psoriatic arthritis (PsA) ; efficacy ; safety ; clinical trialPEDIATRIC-PATIENTSbusiness.industryJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileOligoarticular Juvenile Idiopathic Arthritislcsh:RC925-935Extended oligoarticular juvenile idiopathic arthritis (eoJIA)businessADALIMUMAB
researchProduct